Procaps Group S.A. (PROCF)

OTCMKTS · Delayed Price · Currency is USD
1.290
+0.170 (15.18%)
Sep 5, 2025, 4:00 PM EDT
15.18%
Market Cap2.97B
Revenue (ttm)423.75M
Net Income (ttm)40.34M
Shares Out2.30B
EPS (ttm)0.40
PE Ratio3.23
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,500
Average Volume1,856
Open1.110
Previous Close1.120
Day's Range1.110 - 1.290
52-Week Range0.010 - 3.775
Beta57.05
RSI51.90
Earnings DateAug 29, 2025

About Procaps Group

Procaps Group S.A., together with its subsidiaries, develops, produces, and markets pharmaceutical solutions in South America, Central America, North America, and Europe. It operates in five segments: NextGel, Procaps Colombia, Central America North (CAN), Central America South and North Andes (CASAND), and Diabetrics. The company formulates, manufactures, and markets branded prescription drugs in various therapeutic areas, including feminine care products, pain relief, skin care, digestive health, growth and development, cardiology, vision car... [Read more]

Industry Pharmaceutical Preparations
Founded 1977
Employees 5,500
Stock Exchange OTCMKTS
Ticker Symbol PROCF
Full Company Profile

Financial Performance

In 2023, Procaps Group's revenue was $423.75 million, an increase of 3.37% compared to the previous year's $409.92 million. Earnings were $40.34 million, a decrease of -5.16%.

Financial Statements

News

Procaps Group Secures $130 Million in Equity Investment and Completes Comprehensive Debt Restructuring, as New Investors Take Over Strategic Leadership

New Investors Take Over the Strategic Leadership as Headquarters Move to Bogotá, Marking the Start of a New Chapter of Growth, Execution, and Transformation under Enhanced Governance

5 months ago - GlobeNewsWire

Nasdaq delists Colombia's Procaps Group due to financial shortfalls

Nasdaq recently announced the removal of the Procaps Group due to its failure to complete financial reporting standards on time, a significant decision that illustrates the difficulty that businesses ...

7 months ago - Invezz